Pfizer raises 2026 revenue guidance: Pfizer stock loses 1.08 percent

Published on 10/02/2026 at 16:49 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Q2 revenue reached USD 15.03 billion and adjusted EPS was USD 0.77. Pfizer stock costs EUR 24.74 on October 2, 2026 after EUR 25.01.

Isometrisches 3D-Diagramm einer Pharma-Wertschöpfungskette, Symbolbild für Pfizer Inc — Isometrische 3D-Grafik der Pharma-Wertschöpfungskette zeigt Produktionsprozesse ähnlich Pfizer Inc., ISIN US7170811035, im Überblick, Illustration mit AI erstellt.

Pfizer Inc. (ISIN US7170811035) was trading at EUR 24.74 at Lang & Schwarz on October 2, 2026 at 4:38 p.m. CEST, down 1.08 percent from the prior close of EUR 25.01. The company raised its full-year 2026 revenue guidance midpoint by USD 500.0 million to USD 60.5 billion-USD 62.5 billion, according to ScanX News on September 28, 2026.

Guidance rises on non-COVID products

The updated revenue range compares with the previous USD 59.5 billion-USD 60.5 billion range. ScanX News reported that adjusted diluted earnings per share guidance remained USD 2.80-USD 3.00 for full-year 2026, while second-quarter adjusted diluted earnings per share reached USD 0.77.

Second-quarter 2026 revenue was USD 15.03 billion, up 1.00 percent operationally from a year earlier, according to Zacks on October 1, 2026. The comparison matters because the higher guidance midpoint relies on non-COVID products offsetting weaker COVID-related revenue and patent-cliff pressure.

Analyst target stays below market price

UBS maintained a Hold rating and a USD 27.00 price target for Pfizer in a report released October 2, 2026, as Markets Insider reported. Pfizer's euro quote cannot be compared mathematically with that dollar target, but the differing currencies underline why the Lang & Schwarz price is the relevant reference for German investors.

Market data put Pfizer's NYSE 52-week range at USD 23.62-USD 29.21 on October 2, 2026, with a market capitalization of USD 158.7 billion. The current euro quote sits between those dollar levels only as separate venue context, not as a currency conversion.

Next results date is November 3

Pfizer's next earnings report is scheduled for November 3, 2026, according to TradingView. That date gives investors a defined checkpoint for testing whether the stronger non-COVID portfolio can support the higher annual revenue range while adjusted earnings guidance remains unchanged.

Stock trades below prior close

Pfizer was trading at EUR 24.74 at Lang & Schwarz on October 2, 2026 at 4:38 p.m. CEST, minus 1.08 percent versus the Lang & Schwarz prior close of EUR 25.01 on October 1, 2026. The further course of trading is shown by the continuously updated real-time quote of Pfizer stock.